Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Non-aspirin NSAID use and ovarian cancer mortality

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  2. The genetic landscape of 87 ovarian germ cell tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities

    Research output: Contribution to journalReviewResearchpeer-review

  1. Shared heritability and functional enrichment across six solid cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Preclinical studies suggest that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) may improve survival of ovarian cancer. We examined the association between non-aspirin NSAID use and ovarian cancer mortality.

METHODS: All women in Denmark with a first diagnosis of epithelial ovarian cancer between 2000 and 2012 were identified. We obtained information on drug use, mortality outcomes, and potential confounding factors from nationwide registries. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between postdiagnosis non-aspirin NSAID use (≥1 prescription) and ovarian cancer-specific or other-cause mortality compared with non-use (no prescriptions). The influence of competing risks was evaluated using the sub-distribution hazards model proposed by Fine and Gray.

RESULTS: Among 4117 patients, any postdiagnosis use of non-aspirin NSAIDs was not associated with either ovarian cancer (HR = 0.97, 95% CI = 0.87-1.08) or other-cause (HR = 0.99, 95% CI = 0.77-1.27) mortality, however, inverse associations for ovarian cancer mortality were observed with high cumulative (HR = 0.75, 95% CI = 0.60-0.94) or high-intensity (HR = 0.86, 95% CI = 0.72-1.03) postdiagnosis use of non-aspirin NSAIDs. The associations differed substantially with histological subtype of ovarian cancer, with only inverse associations observed for serous ovarian cancer (HR = 0.87, 95% CI = 0.77-0.99). Among a smaller number of patients with a non-serous tumor, postdiagnosis non-aspirin NSAID use was associated with increased ovarian cancer mortality.

CONCLUSIONS: Any postdiagnosis use of non-aspirin NSAIDs did not influence ovarian cancer mortality overall, however, more intensive use was associated with improved survival of serous ovarian cancer.

Original languageEnglish
JournalGynecologic Oncology
Volume150
Issue number2
Pages (from-to)331-337
Number of pages7
ISSN0090-8258
DOIs
Publication statusPublished - Aug 2018

    Research areas

  • Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Carcinoma, Ovarian Epithelial, Cohort Studies, Cystadenocarcinoma, Serous/diagnosis, Denmark/epidemiology, Female, Humans, Middle Aged, Neoplasms, Glandular and Epithelial/diagnosis, Ovarian Neoplasms/diagnosis, Proportional Hazards Models, Time Factors

ID: 56089900